Overview

Navitoclax and Abiraterone Acetate With or Without Hydroxychloroquine in Treating Patients With Progressive Metastatic Castrate Refractory Prostate Cancer

Status:
Terminated

Trial end date:
2016-03-03

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone. The investigators hope that these combinations of medicines will result in prostrate cancer cells dying. This study will see if overcoming diseases resistance to abiraterone will restore sensitivity to androgen deprivation therapy.

Phase:

Phase 2

Details

Lead Sponsor:

Rutgers, The State University of New Jersey

Collaborators:

AbbVie
National Cancer Institute (NCI)
Rutgers Cancer Institute of New Jersey

Treatments:

Abiraterone Acetate
Hydroxychloroquine
Navitoclax